Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal
Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite...
Continue Reading →
